Low adenylate kinase 5 expression is predictive of poor prognosis and promotes tumour growth by regulating the cell-cycle pathway.
adenylate kinase 5
colon adenocarcinoma
prognosis
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
24
05
2022
received:
24
11
2021
accepted:
27
05
2022
pubmed:
2
6
2022
medline:
11
8
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Colon adenocarcinoma (COAD) is one of the most common malignant tumours of the digestive system. Specific molecular markers play an important role in COAD diagnosis and therapy. Adenylate kinase 5 (AK5) is an enzyme that is related to energy metabolism and cancer. However, the exact role of AK5 in the progression of COAD is still unclear. In this study, the expression of AK5 in tissue samples and non-cancerous tissues of COAD patients was assessed by the bioinformatics method and western blot. Kaplan-Meier survival analysis and Cox regression analysis evaluated the prognostic significance of AK5. The biological function of AK5 in tumour progression was assessed by MTT assay, colony formation assay, transwell assay, wound healing assay, western blot and mice xenograft models. The results showed that AK5 expression in tumour tissues was lower than in non-cancerous tissues. Notably, the patients with high AK5 expression possessed a longer overall survival than the low expression patients, and low AK5 expression promoted proliferation and metastasis in COAD cells by regulating the cell-cycle pathway. Importantly, in vivo results showed that reduced AK5 expression is required for tumour growth. This study confirmed the significant role of AK5 in the development and progression of COAD. Therefore, low AK5 expression levels can be an independent prognostic biomarker, which provides new sight for the clinical diagnosis and target therapy of COAD.
Identifiants
pubmed: 35642328
doi: 10.1111/1440-1681.13680
doi:
Substances chimiques
Adenylate Kinase
EC 2.7.4.3
adenylate kinase 5
EC 2.7.4.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
970-978Informations de copyright
© 2022 John Wiley & Sons Australia, Ltd.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
Tam SY, Wu VWC. A review on the special radiotherapy techniques of colorectal cancer. Front Oncol. 2019;9:208.
Jakobsen A, Andersen F, Fischer A, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 2015;54(10):1747-1753.
Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic therapy in colorectal cancer. Cancer J. 2018;24(4):165-170.
Dzeja P, Terzic A. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci. 2009;10(4):1729-1772.
Carrasco AJ, Dzeja PP, Alekseev AE, et al. Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels. Proc Natl Acad Sci U S A. 2001;98(13):7623-7628.
Dzeja PP, Chung S, Faustino RS, Behfar A, Terzic A. Developmental enhancement of adenylate kinase-AMPK metabolic signaling axis supports stem cell cardiac differentiation. PLoS One. 2011;6(4):e19300.
Ng AS, Kramer J, Centurion A, et al. Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis. J Neuroimmunol. 2015;287:31-35.
Ansoleaga B, Jove M, Schluter A, et al. Deregulation of purine metabolism in Alzheimer's disease. Neurobiol Aging. 2015;36(1):68-80.
Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer. 2005;116(3):407-414.
Zhang LH, Wang Z, Fan QQ, et al. AK5, a novel prognosis marker, inhibits apoptosis and promotes autophagy as well as proliferation in human gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(22):9900-9906.
Morsczeck C, Hullmann M, Reck A, Reichert TE. The cell cycle regulator protein P16 and the cellular senescence of dental follicle cells. Mol Cell Biochem. 2018;439(1-2):45-52.
Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63-71.
Sun X, Wang T, Zhang C, et al. S100A16 is a prognostic marker for colorectal cancer. J Surg Oncol. 2018;117(2):275-283.
Kosaka N, Kogure A, Yamamoto T, et al. Exploiting the message from cancer: the diagnostic value of extracellular vesicles for clinical applications. Exp Mol Med. 2019;51(3):1-9.
Lai Y, Hu X, Chen G, Wang X, Zhu B. Down-regulation of adenylate kinase 5 in temporal lobe epilepsy patients and rat model. J Neurol Sci. 2016;366:20-26.
Hansel DE, Rahman A, House M, et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res. 2004;10(18 Pt 1):6152-6158.
Roesli C, Borgia B, Schliemann C, et al. Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. Cancer Res. 2009;69(13):5406-5414.
Xin F, Yao DW, Fan L, Liu JH, Liu XD. Adenylate kinase 4 promotes bladder cancer cell proliferation and invasion. Clin Exp Med. 2019;19(4):525-534.
Liu H, Pu Y, Amina Q, et al. Prognostic and therapeutic potential of adenylate kinase 2 in lung adenocarcinoma. Sci Rep. 2019;9(1):17757.
Zhang XY, Zhou LL, Jiao Y, et al. Adenylate kinase 7 is a prognostic indicator of overall survival in ovarian cancer. Medicine (Baltimore). 2021;100(1):e24134.
Lanczky A, Nagy A, Bottai G, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160(3):439-446.
Ning K, Wang T, Sun X, et al. UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer. J Surg Oncol. 2017;115(8):932-940.
Chen Z, Zhu Y, Dong Y, et al. Overexpression of TrpC5 promotes tumor metastasis via the HIF-1alpha-twist signaling pathway in colon cancer. Clin Sci (Lond). 2017;131(19):2439-2450.